As Europe is weeks ahead, we know the 5th wave is upon us now as of late November, 2022. As micro cap investors, I recommend you keep an eye on a few of these names:

• $OCGN
• $NRXP
• $RLFTF

On November 3rd, 2021 The World Health Organization (WHO) granted approval for emergency use to India’s government-backed Covid-19 vaccine, Covaxin. This is related to Ocugen ticker $OCGN.

After Australia, its trans-Tasman neighbour, New Zealand, too, has recognied Covaxin and Covishield, the two most widely-used vaccines in India’s vaccination drive against the coronavirus disease (Covid-19).

Before the WHO news $OCGN spiked to $15, now it’s back down to $7 in terms of stock price Google Sheets. $NRXP is also way down from its highs. It’s approaching $5, just because the FDA rejected its first attempt with Zyesami. I believe these are all potential buy the dip plays, and I think FOMO will drive them up as the next wave ramps up.

When we look at Germany and Eastern Europe, we realize how Delta waves can get worse than anticipated. The U.S. has pockets of very low vaccination rates. Combined with vaccine efficacy dropping and pandemic fatigue, it really is the perfect storm.

Unlike Cisco DCF, NRx $NRXP says it looks forward to working with the FDA to complete the chemistry, manufacturing, and controls (CMC) review that will ultimately be required for any potential drug approval. It knows how the process works. Picking those two up below $5 could be a possible play and $RLFTF below $0.05 as well. It’s risky but known the charts of these companies, the volatility swings can be truly impressive.

Ocugen partnered with India’s Bharat Biotech to distribute its Covid vaccine, Covaxin, in a timely manner in North America. Even as Covaxin slowly gets mainstream approval for the rest of the world, it’s somewhat unlikely it will even happen in the U.S. $NVAX on that front makes more sense, but don’t tell this to meme stock investors and wall-street hedge funds who think they understand the Reddit army.

Still the $OCGN story is making steady progress. The World Health Organization (WHO) recently offered Covaxin Emergency Use Listing. This is positive for vaccine developer Bharat as it may accelerate the distribution of the vaccine in areas where it’s already been authorized or about to be authorized.

• Ocugen needs to win Emergency Use Authorization for COVID-19 vaccine Covaxin in Canada. That would be the catalyst of hope for buyers of this stock at this point, similar to Cisco WACC.
• Canadian Emergency Use Authorization would certainly make Ocugen more valuable and the company has rights in Canada and the US. It’s already submitted an application in Canada, but we haven’t got a lot of update since the 2nd quarter earnings call when management said that they were ready to answer questions from regulators at Health Canada, which besides that, we don’t have any other updates.

I’m Canadian and I trust Moderna, but not Pfizer as much (and certainly not AZ). I either want the best MRNA vaccine, or if I’m not comfortable with that technology, a widely used less intimidating vaccine. With booster shots needed in January, 2022, Covaxin pretty much fits the bill with pretty high Excel stock price.

In the U.S., Ocugen has filed an application with regulators to launch a new clinical trial. The study would support potential approval of Covaxin. Ocugen has submitted an IND, which is Investigational New Drug application. You have to do that before you start a clinical trial and so they want to run a Phase 3 bridging study.

So all in all, I think $NRXP may be the better buy the dip than $CSCO which has a stable Cisco Intrinsic Value, but both are potentially really good if you have a lot of risk tolerance. Follow the 5-year chart. The volatility of both names have meme-like quality that’s predictable at least.

The pandemic is not over and 2022 could actually be somewhat worse since new variants of Delta appear to be forthcoming. Delta plus is around 10% more contagious. Countries are less able to get people to follow strict measures. The crisis point we are seeing in November, 2021 in Europe will likely shift to where we live as well.

According to short interest api, Covaxin is an ideal safe booster shot and vaccine ideal for kids globally. As for $NRXP Prior to the COVID pandemic, ZYESAMI was never manufactured as a commercial drug for intravenous use. However it’s ability to reduce mortality in ICUs is important as nursing shortages are going to get insane.

At the time of writing:

$OCGN is $7.65 (a buy at $6.80)

$NRXP is $5.36 (a buy at $4.90)

$RLFTF (OTC) is $0.062 ( a buy at $0.047).